Stephanie Davis
Stock Analyst at Barclays
(1.20)
# 3,061
Out of 4,667 analysts
101
Total ratings
33.33%
Success rate
-15.19%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $4.42 | +13.12% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $49.90 | +50.30% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $7.22 | -3.05% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $4.31 | +39.21% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $11.31 | +67.99% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $243.20 | +19.24% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $22.23 | +7.96% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $120.34 | +10.52% | 2 | Nov 4, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $39 → $58 | $41.82 | +38.69% | 2 | Oct 31, 2024 | |
| TALK Talkspace | Maintains: Equal-Weight | $2 → $3 | $3.16 | -5.06% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $154 → $168 | $161.32 | +4.14% | 3 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $0.75 | $0.95 | -21.05% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5.5 → $5 | $3.56 | +40.45% | 10 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $237.85 | +4.69% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $30.92 | -22.38% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $18.52 | +56.59% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $9.00 | +277.78% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $13.98 | +143.20% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $210.63 | +10.62% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $7.36 | +130.98% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $102.96 | -26.18% | 5 | Jun 7, 2022 |
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $4.42
Upside: +13.12%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $49.90
Upside: +50.30%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $7.22
Upside: -3.05%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $4.31
Upside: +39.21%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $11.31
Upside: +67.99%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $243.20
Upside: +19.24%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $22.23
Upside: +7.96%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $120.34
Upside: +10.52%
Omnicell
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $41.82
Upside: +38.69%
Talkspace
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $3.16
Upside: -5.06%
Oct 23, 2024
Maintains: Equal-Weight
Price Target: $154 → $168
Current: $161.32
Upside: +4.14%
Oct 10, 2024
Maintains: Underweight
Price Target: $0.75
Current: $0.95
Upside: -21.05%
Oct 9, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $5
Current: $3.56
Upside: +40.45%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $237.85
Upside: +4.69%
Jul 2, 2024
Initiates: Overweight
Price Target: $24
Current: $30.92
Upside: -22.38%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $18.52
Upside: +56.59%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $9.00
Upside: +277.78%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $13.98
Upside: +143.20%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $210.63
Upside: +10.62%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $7.36
Upside: +130.98%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $102.96
Upside: -26.18%